Marshall Wace, LLP Savara Inc Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.66 - $5.34 $900,751 - $1.31 Million	246,107 Added 420.03%	304,700 $1.23 Million
Q1 2024 May 15, 2024	BUY	$4.19 - $5.59 $245,504 - $327,534	58,593 New	58,593 $291,000
Q1 2023 May 15, 2023	BUY	$1.6 - $2.82 $53,332 - $93,999	33,333 New	33,333 $64,000
Q1 2020 May 15, 2020	SELL	$1.91 - $4.08 $69,848 - $149,205	-36,570 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$0.71 - $4.91 $25,964 - $179,558	36,570 New	36,570 $164,000

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.